Fmoc-Lys(Alloc)-OH

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-Lys(Alloc)-OH
• 英文别名: Fmoc-K(Alloc)-OH；Fmoc-Lys-(Alloc)；N2-Fmoc-N6-[(allyloxy)carbonyl]-L-lysine；2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid
• 化学式: C₂₅H₂₈N₂O₆
• mdl: MFCD04221436
• 分子量: 452.507
• InChiKey: OJBNDXHENJDCBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Fmoc-Lys(Alloc)-OH 、 芴甲氧羰基-DL-丙氨酸 、 N²-(((9H-fluoren-9-yl)methoxy)carbonyl)-N⁶-(tert-butoxycarbonyl)lysine 、 Fmoc-Tyr(tBu)-OH 、 alkaline earth salt of/the/ methylsulfuric acid 生成 cyclo[Succ-AK(Boc)IY(tBu)R(Pbf)K]G-OH
  参考文献：
  名称：

  Loops on loops: generation of complex scaffolded peptides presenting multiple cyclic fragments

  摘要：

  通过分步固相合成法和片段缩合法同时生成了支架肽，支架肽通过一个环状拟肽支架以位点选择性的方式呈现出两种不同的环状肽片段，证明这两种方法都足以生成复杂的支架肽。

  DOI：

  10.1039/b403720k

文献信息

• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• New effector conjugates, process for their production and their pharmaceutical use
  申请人：Klar Ulrich

  公开号：US20050234247A1

  公开（公告）日：2005-10-20

  Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recognition units. The pharmaceutical use of conjugates for treating proliferative or angiogenesis-associated processes is described.

  描述了与适当的生物分子（作为识别单元）的环丙沙星和环丙沙星衍生物（作为效应物）的共轭体。它们的生产是通过将效应物与适当的连接剂反应，然后将产生的化合物与识别单元结合。描述了共轭体在治疗增殖或血管生成相关过程的药物用途。
• Cell lines
  申请人：MEDIMMUNE LIMITED

  公开号：US10253345B2

  公开（公告）日：2019-04-09

  There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

  除其他外，还提供了一种稳定真核细胞系的方法，该细胞系表达 PylRS 和 tRNAPyl，适于加入编码含有一个或多个由无意义密码子编码的非天然氨基酸的目标蛋白质的基因，该方法包括在减少或消除 tRNAPyl 表达对细胞活力和/或细胞生长的不利影响的条件下培养所述细胞系。
• Modified lipidated Relaxin B chain peptides and their therapeutic use
  申请人：Sanofi

  公开号：US10988523B2

  公开（公告）日：2021-04-27

  Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.

  本文提供了一种具有生物活性的单链松弛素肽，其分子式如下（I）： Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; 或其盐或溶解物。还提供了包含至少一种本发明多肽的药物组合物，以及用作药物的多肽或药物组合物。